Investigational drug · Phase 3
REGN9933
Also called: amrecibart
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Atrial Fibrillation (AF), Peripheral Artery Disease (PAD), Venous Thromboembolism (VTE).
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
4 still active
All registered trials
9
Any phase or sponsor naming "REGN9933"
First trial start
2024
Sep 20, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "REGN9933", any sponsor or status.
Conditions studied
As listed on its trial records.
- Atrial Fibrillation (AF)
- Peripheral Artery Disease (PAD)
- Venous Thromboembolism (VTE)
- Venous Thromboembolism
Approved drugs for the same conditions: Atrial fibrillation · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "REGN9933" as an intervention, largest first.
- Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery DiseasePivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07318610 · 7,050 participants (planned) · Start Jul 10, 2026 · Primary completion Aug 18, 2029
Drug: REGN7508; REGN9933 and 2 more · For: Peripheral Artery Disease (PAD)
Sites: Alexander City, Alabama; Avondale, Arizona; Little Rock, Arkansas · 34 sites in all
- Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is UnsuitablePivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07430956 · 2,628 participants (planned) · Start Apr 3, 2026 · Primary completion Mar 28, 2029
Drug: REGN7508; REGN9933 and 1 more · For: Atrial Fibrillation (AF)
Sites: Dothan, Alabama; Glendale, Arizona; Little Rock, Arkansas · 45 sites in all
- Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Central Catheter (PICC)Pivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07697599 · 1,908 participants (planned) · Start Sep 7, 2026 · Primary completion Jun 25, 2029
Drug: REGN7508; REGN9933 and 1 more · For: Venous Thromboembolism (VTE)
Sites: Tbilisi, Georgia
- Safety in Adult Participants With Atrial Fibrillation Who Are Treated With AnticoagulationPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07175428 · 1,200 participants (planned) · Start Oct 20, 2025 · Primary completion Feb 9, 2027
Drug: REGN7508; REGN9933 and 1 more · For: Atrial Fibrillation (AF)
Sites: Dothan, Alabama; Fairhope, Alabama; Covina, California · 91 sites in all
- A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult ParticipantsPivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05618808 · 373 participants · Start May 24, 2023 · Primary completion May 27, 2024
Drug: REGN9933; Enoxaparin and 1 more · For: Venous Thromboembolism
Sites: Genk, Belgium; Pleven, Bulgaria; Ajax, Canada · 16 sites in all
- Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult ParticipantsPivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06444178 · 224 participants · Start Sep 30, 2024 · Primary completion Apr 7, 2025
Drug: Aspirin; REGN9933 and 2 more · For: Healthy Volunteers
Sites: Leeds, United Kingdom
- A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)Pivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06299111 · 195 participants · Start Sep 20, 2024 · Primary completion Mar 27, 2026
Drug: REGN9933; REGN7508 and 1 more · For: Venous Thromboembolism
Sites: Los Angeles, California; Miami, Florida; Boston, Massachusetts · 23 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05102136 · 56 participants · Start Oct 27, 2021 · Primary completion Apr 4, 2023
Drug: REGN9933; Placebo · For: Healthy Volunteers
Sites: Edegem, Belgium
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07759167 · 36 participants (planned) · Start Sep 17, 2026 · Primary completion Apr 2, 2027
Drug: REGN9933; REGN7508 and 2 more · For: End-Stage Kidney Disease (ESKD)
Sites: Ghent, Belgium
Newest research
PubMed records naming it or its code names, newest first.
- Amrecibart and cenvacibart for the prevention of catheter-related thrombosis (ROXI-CATH): a double-blind, randomised, placebo-controlled, phase 2 trial.
Zwicker JI, Kithcart AP, Kaplan J, et al. · Lancet Haematol 2026
- Anticoagulation with the mechanistically distinct FXI/FXIa antibodies amrecibart (REGN9933A2) and cenvacibart (REGN7508Cat).
Chalothorn D, Kithcart AP, Marin E, et al. · Blood 2026
- Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials.
Weitz JI, Kithcart AP, O'Brien MP, et al. · Lancet 2025
Also in development for Atrial Fibrillation (AF)
- REGN7508CenvacibartPhase 312 trials
Regeneron · Atrial Fibrillation (AF), Venous Thromboembolism (VTE), Venous Thromboembolism
- AbelacimabMAA868Phase 33 trials
Anthos Therapeutics, Inc. · Atrial Fibrillation (AF), Stroke
- AP31969Phase 21 trial
Acesion Pharma · Atrial Fibrillation (AF)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Regeneron.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.